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Abstract
 
During maturation, dendritic cells (DCs) regulate their capacity to process and present major
histocompatibility complex (MHC) II–restricted antigens. Here we show that presentation of
exogenous antigens by MHC I is also subject to developmental control, but in a fashion strik-
ingly distinct from MHC II. Immature mouse bone marrow–derived DCs internalize soluble
ovalbumin and sequester the antigen intracellularly until they receive an appropriate signal that
induces cross presentation. At that time, peptides are generated in a proteasome-dependent
fashion and used to form peptide–MHC I complexes that appear at the plasma membrane. Un-
like MHC II, these events do not involve a marked redistribution of preexisting MHC I mole-
cules from intracellular compartments to the DC surface. Moreover, out of nine stimuli well
known to induce the phenotypic maturation of DCs and to promote MHC II presentation,
only two (CD40 ligation, disruption of cell–cell contacts) activated cross presentation on MHC
I. In contrast, formation of peptide–MHC I complexes from endogenous cytosolic antigens
occurs even in unstimulated, immature DCs. Thus, the MHC I and MHC II pathways of antigen
presentation are differentially regulated during DC maturation.
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Introduction
 
While MHC II molecules associate with peptides derived
from exogenous antigens internalized by endocytosis,
MHC I molecules are classically thought to present immu-
nogenic peptides of endogenous origin (1). However, ex-
ogenous antigens can also enter the MHC I pathway of
APCs by a process called “cross presentation” (2). Func-
tionally, cross presentation is thought to be crucial for
priming CD8-dependent responses against tumor cells or
pathogens which are not directly expressed by APCs (3).
Cell biologically, the mechanism of cross presentation is of
interest because it appears to involve overcoming a nor-
mally impenetrable topology barrier. Internalized antigen
in the lumen of endocytic vesicles must egress into the cy-
tosol where it can become a substrate for proteasome-
dependent peptide generation.
Among APCs, DCs are the most efficient at initiating
antigen-specific immune responses, inducing differentia-
tion of both naive CD4
 
 
 
 and CD8
 
 
 
 T cells (4). They are
also adept at cross presentation (5, 6). In their immature
state, DCs reside in peripheral tissues where they detect and
capture incoming pathogens. DCs then begin a maturation
process characterized by a series of dramatic phenotypic
and functional changes (7). Maturation is triggered by vari-
ous inflammatory mediators and microbial products, all of
which produce DCs with common cell surface phenotype
including dramatic increases in MHC II and costimulatory
molecule expression. In contrast, the cytokines that mature
DCs secrete can vary markedly. Different stimuli thus pro-
duce qualitatively different states of maturation, facilitating
the DC’s ability to polarize T cell responses (8).
The cell biology of DC maturation is a subject of intense
interest with considerable progress having been made
charting the regulation of the MHC II pathway (7, 9). In
immature DCs, newly synthesized MHC II accumulates in
late endosomal and lysosomal compartments. Upon receipt
of a maturation signal, these MHC II molecules become
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more efficiently loaded with peptide (10, 11) and are then
transferred to the cell surface (12, 13). Newly synthesized
MHC II now also avoids lysosomes on route to the plasma
membrane (14).
In contrast, little is known about how maturing DCs
modulate the function of MHC I. In some DC popula-
tions, the maturation-induced increase in MHC I surface
expression is thought to reflect increased synthesis and
posttranslational stability (15, 16). In Langherans cells, on
the other hand, at least some MHC I may accumulate in
lysosomal compartments (17), suggesting that increased cell
surface expression may in part reflect the recruitment of
MHC I sequestered in lysosomes.
It is well established that DCs cross present exogenous
antigen after uptake by phagocytosis or Fc receptor-medi-
ated endocytosis (6, 18, 19). However, which if any aspects
of this process are controlled by maturation remain unclear.
Recent data do support the possibility that DCs regulate
cross presentation at least in some fashion. In vivo, interac-
tion between APCs and T-helper cells via CD40–CD40L
has been suggested to activate APCs to become fully com-
petent for CD8
 
 
 
 T cell priming (20–22). In vitro, TCR
binding to MHC II has also been reported to induce MHC
I cross presentation by DCs (23). Furthermore, ubiquiti-
nated proteins appear transiently in aggresome-like struc-
tures upon induction of DC maturation (24). These “DALIs”
may sequester endogenous proteins to allow more efficient
processing of exogenous proteins.
Here, we show that cross presentation is subject to de-
velopmental regulation in DCs. Most interestingly, the
presentation of exogenous antigen on MHC I is activated
by only a subset of the signals which activate MHC II–depen-
dent presentation, indicating that the two pathways have
unexpectedly distinct patterns of regulation.
 
Materials and Methods
 
Mouse DC Culture.
 
B6D2F1 and C57BL/6J mice were pur-
chased from The Jackson Laboratory. Bone marrow–derived
DCs were prepared as described previously (14). At day 4, the
cultures contained many aggregates of immature DCs loosely at-
tached to the monolayer. To mature the DCs, we either disag-
gregated DC clusters by gentle pipetting and added LPS (10 ng/
ml, 
 
Escherichia coli
 
 type 0111.B4; Sigma-Aldrich), added CpG
DNA (TCCATGACGTTCCTGACGTT, 10 nM), bacteria (0.5
 
 
 
l/ml MAX Efficiency DH5 
 
 
 
 competent cells; Invitrogen), poly
IC (20 
 
 
 
g/ml; Sigma-Aldrich), TNF
 
 
 
 (10 ng/ml; PeproTech),
IFN-
 
 
 
 (10 ng/ml; PeproTech), anti-CD40 mAb (HM40–3, 10
 
 
 
g/ml; BD Biosciences), CD4
 
 
 
 T cell hybridoma DO.11.10
(1 T cell:1 DC ratio).
 
MHC Class I–restricted Antigen Presentation Assays.
 
OVA
(grade VI; Sigma-Aldrich or Worthington), BSA (fraction V;
Sigma-Aldrich) at 1 mg/ml was added to immature DCs for 2 h.
Presentation of OVA epitope 257–264 in a H-2K
 
b
 
 background
was monitored using purified CD8
 
 
 
 T cells from OT.1 TCR
transgenic mice provided by Kim Bottomly (Yale Medical
School, New Haven, CT). 2 
 
  
 
10
 
5
 
 DCs minus or plus a matu-
ration stimulus were cultured with 1 
 
 
 
 10
 
5
 
 OT.1 T cells in 96-
well microtiter plates in RPMI 1640–5% FCS. In some cases,
 
the 96-well plates were coated with anti-CD28 Ab (10 
 
 
 
g/ml;
BD Biosciences) overnight at 4
 
 
 
C. The DCs were fixed in 1%
paraformaldehyde for 30 min on ice. CD8
 
 
 
 T cells were puri-
fied from spleen and lymph node suspensions by negative selec-
tion using CD8
 
 
 
 cell isolation kit (Miltenyi Biotec). T cell
responses were monitored at 24 h by measuring IL-2 accumula-
tion in the supernatant by ELISA (BD Biosciences). Data are
from triplicate cultures.
 
MHC Class II–restricted Antigen Presentation Assays.
 
Presenta-
tion of OVA epitope 323–339 in an I-A
 
d
 
 background was moni-
tored using the CD4
 
 
 
 T cell hybridoma DO.11.10 (obtained
from Philippa Marrack, National Jewish Hospital, Denver, CO).
10
 
5
 
 DCs that were exposed to OVA or BSA were applied to 2 
 
 
 
10
 
5
 
 CD4
 
 
 
 T cells in 96-well microtiter plates. T cell responses
were monitored as described above.
 
Separation of CD11c-positive DCs from CD11c-negative Cells.
 
DCs were incubated with magnetic micro-beads conjugated to
anti–mouse CD11c mAb (clone N418; Miltenyi Biotec) for 15
min at 4
 
 
 
C. CD11c-positive DCs were then separated by passing
cells over a MACS MS
 
 
 
 column held in a VarioMACS magnetic
separator (Miltenyi Biotec).
 
Antibodies and Immunofluorescence.
 
Immunofluorescence pat-
terns were visualized with confocal microscopy as described (14).
MHC II proteins were detected using TIB 120, a rat mAb, MHC I
H-2K
 
b
 
 using P8, a rabbit polyclonal Ab (gift of Hidde Ploegh, Har-
vard Medical School, Boston, MA), Lamp-2 using GL2A7, a rat
mAb (14), ER-resident KDEL proteins using anti-KDEL, a mouse
mAb (StressGen Biotechnologies), the Golgi apparatus using anti-
GM130, a mouse mAb (BD Transduction Laboratories), and OVA
using a rabbit polyclonal Ab (Sigma-Aldrich). All secondary Abs
were purchased from Jackson ImmunoResearch Laboratories.
 
Flow Cytometry Assays.
 
Cells were stained for 30 min on ice
with either FITC or PE anti-MHC II I-A
 
b
 
 (AF6–120.1), PE
anti-MHC I H2-K
 
b
 
 (AF6–88.5), PE anti-CD86 (GL1), Cy-
chrome anti-CD11c (HL3), FITC anti-H2-K
 
b
 
/OVA complex
(25.D1.16; gift of Dr. Ronald Germain, National Institutes of
Health, Bethesda, MD) washed, and then evaluated on a FACS-
Calibur™ (Becton Dickinson). All Abs including isotype controls
were purchased from BD Biosciences.
 
Western Blot.
 
DCs were lysed in TBS-1% Triton. Proteins
were separated on a 5–15% acrylamide Ready Gel (Bio-Rad Lab-
oratories) under reducing conditions, transferred to nitrocellulose
and detected with 216 F, a rabbit anti-MHC I heavy chain (HC)
 
*
 
Ab (gift of Hidde Ploegh), and HRP-goat anti-rabbit IgG Ab
(Sigma-Aldrich). Blots were visualized using Super Signal West
Pico (Pierce Chemical Co.).
 
Immunoprecipitation and Surface Biotinylation.
 
1.5 
 
 
 
 10
 
7
 
 cells
were pulsed-labeled for 10 min with 1.5 ml of 3 mCi of 
 
35
 
S Pro-
tein Labeling Mix (NEN Life Science Products) in MEM with-
out methionine/cysteine (ICN Biomedicals) 
 
  
 
10% dialyzed
FBS (GIBCO BRL) and chased for various times in DC growth
medium with a fivefold excess of unlabeled methionine and cys-
teine. Cells were then washed in cold PBS and incubated with
1.5 mg/ml of EZ-Link Sulfo-NHS-LC-LC-biotin (Pierce
Chemical Co.) for 30 min on ice. The reaction was stop by add-
ing 100 mM final glycine pH 8.0 and washing the cells in PBS-
100 mM glycine. Cells were lysed in 1 ml lysis buffer (TBS-
0.5% Triton, 20 mM glycine, and protease inhibitor cocktail
[Roche]). Lysates were precleared with protein A sepharose
(Zymed Laboratories). 100 
 
 
 
l aliquots were denatured by add-
 
*
 
Abbreviation used in this paper:
 
 HC, heavy chain.T
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ing 2% final SDS at 100
 
 
 
C and then diluted into 1 ml lysis
buffer. Proteins were immunoprecipitated using “Winken,” a
rabbit anti–mouse H-2K
 
b
 
 cytoplasmic tail Ab bound to protein
A sepharose, then washed in lysis buffer (total MHC I). The re-
maining 900 
 
 
 
l of lysate were immunoprecipitated with P8 Ab
by the same protocole. Samples were eluted from beads in 100
 
 
 
l SDS buffer (20 mM Tris HCl, pH 7.4, 100 mM NaCl, 10
mM glycine, 2% SDS) and boiled. 20 
 
 
 
l were analyzed directly
(total HC–
 
 
 
2
 
M complexes). The remaining 80 
 
 
 
l were diluted
into 1 ml lysis buffer and biotinylated proteins were immuno-
precipitated with Ultralink immobilized NeutrAvidin™ biotin-
binding protein (Pierce Chemical Co.), then washed in 0.1%
SDS-lysis buffer (surface biotinylated HC-
 
 
 
2
 
M complexes).
Proteins were separated on a 5–15% acrylamide Ready Gel un-
der reducing conditions.
 
Retrovirus Generation and Transduction.
 
A fragment of OVA
(obtained from Terry Potter, National Jewish Hospital, Denver,
CO) containing nucleotides 63 to 1161 was amplified by PCR
and subcloned into the pCMV/myc/cyto vector (Invitrogen) us-
ing the SalI and NotI sites. The resulting fusion construct was
cloned by PCR into LZRS-pBMN using EcoRI sites. This viral
vector was transfected into 
 
 
 
NX-ecotropic cells, and virus was
collected and used to infect DC progenitors (12).
 
Cell Fractionation.
 
Cells were homogenized in sucrose buffer
(0.2 M sucrose, 10 mM imidazole, pH 7, 2 mM EDTA, protease
inhibitor cocktail) by 20–30 passes in ball-bearing homogenizer
(14). Postnuclear supernatants were centrifuged at 50,000 
 
g
 
 for 30
min to separate cytosolic and membrane/vesicle fractions. OVA
and cathepsin L (Cat L) were detected by Western blot using
“Samson” an anti-OVA Ab raised in rabbit by immunization
with OVA and a rabbit Ab to Cat L (gift of Ann Erickson, Uni-
versity of North Carolina, Chapel Hill, NC), respectively.
 
Results
 
Surface MHC I Expression Is Increased during Maturation of
Mouse Bone Marrow–derived DCs.
 
We first investigated
whether maturation of mouse bone marrow-derived DCs
was accompanied by an increase in cell surface expression
of MHC I as observed previously for human DCs (16, 17)
and the D1 mouse DC-like cell line (15). CD11c
 
 
 
 DCs
were enriched (
 
 
 
95%) and then activated using LPS. After
a lag of 
 
 
 
7 h, MHC I began to increase such that by 30 h
its expression was 7-fold higher than in immature DCs.
MHC II and CD86 expression began to increase shortly af-
ter LPS addition, reaching levels 12-fold and 
 
 
 
30-fold
higher (respectively) at 30 h (Fig. 1 A).
Because a portion of the MHC II is recruited from a
preexisting lysosomal pool, we asked if DCs also contained
an intracellular pool of MHC I. Using an Ab to the HC-
 
 
 
2
 
M complex, intracellular MHC I staining was weak in
immature DCs, exhibiting a fine punctate nearly reticular
pattern reminiscent of the ER; some MHC I also accumu-
lated in the perinuclear region (Fig. 1 B). The MHC I pat-
tern did not, however, precisely overlap with that obtained
using an Ab to all KDEL-containing ER content proteins
(ER marker). The perinuclear pattern was similar to the
staining obtained with an Ab to GM130, a marker for cis-
ternal Golgi elements (Golgi marker), but was distinct from
the MHC II-positive lysosomal structures characteristic of
immature DCs. Similar MHC I staining was observed in
MHC II-negative cells (e.g., macrophages or DC progeni-
tors) present in the cultures (unpublished data). Thus, the
MHC I pattern was not specific for DCs and may reflect
the distribution of all newly synthesized plasma membrane
proteins which often appear to accumulate in the Golgi re-
gion en route to the surface.
The pattern changed dramatically after maturation (Fig.
1 B). In mature DCs, most of the MHC I now appeared
together with MHC II at the plasma membrane (top row).
A fraction of the MHC I did remain intracellularly in a
Golgi-like pattern (bottom row).
Thus, HC-
 
 
 
2
 
M complexes do not appear to be seques-
tered in intracellular compartments in immature DCs.
However, we could not eliminate the possibility that the
cells contained a pool of unassembled MHC I since avail-
able Abs to mouse MHC I do not recognize free HC by
immunofluorescence. To address this possibility, we moni-
tored the expression of total HC by Western blot (Fig. 1 A,
inset). After LPS addition, the increase in total HC in-
creased at a rate very similar to the rate of increase of MHC
I at the cell surface suggesting that the increased surface ex-
pression could be accounted for by new protein synthesis.
We next determined the kinetics of appearance of MHC
I at the surface by pulse-chase radiolabeling followed by
cell surface biotinylation. The radiolabeling itself probably
stimulated DCs to mature because the 
 
35
 
S methionine/cys-
teine mix produced in bacteria contains agents such as LPS.
Since the entire experiment lasted 
 
 
 
4 h, however, any al-
teration of MHC I traffic should be minimal (e.g., the
amounts of total and surface MHC I were found not to
change at times 
 
 
 
7 h after LPS treatment [Fig. 1 A]).
During the initial 15 min pulse, immunoprecipitation of
total HC from whole cell lysates indicated that mature DCs
synthesized 
 
 
 
2.6-fold more HC than did immature DCs
(Fig. 1 C, top row, t 
 
  
 
0) despite the fact that both DC
types exhibited comparable amounts of overall protein syn-
thesis (unpublished data). Although slightly more unstable
in immature DCs, quantitation revealed that the HC was
turned over at comparable rates in mature and immature
cells (Fig. 1 C, right, top panel).
The formation of intact HC-
 
 
 
2
 
M complexes (measured
by immunoprecipitation with an Ab that detects only the
complex) was also 
 
 
 
2.6-fold higher in mature as compared
with immature DCs (Fig. 1 C, middle panel, t 
 
  
 
0). More-
over by 15 min of chase, the fraction of total HC that had
assembled into HC-
 
 
 
2
 
M complexes was the same in both
samples. Thus, assembly was at best only slightly more effi-
cient in mature DCs, suggesting that maturation did not
dramatically regulate the efficiency of HC-
 
 
 
2
 
M complex
formation. As found for total HC, HC-
 
 
 
2
 
M complexes
were lost at comparable rates (Fig. 1 C, middle, right
panel). Note also that the apparent decrease in mobility of
HC in immature DCs reflected a slight gel distortion.
Most importantly, the intact HC-
 
 
 
2
 
M complexes were
delivered to the plasma membrane with nearly the same ki-
netics (Fig. 1 C, bottom panel). As expected from the dif-
ferential rates of synthesis, the absolute amounts of MHC IT
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reaching the surface (and becoming accessible to biotinyla-
tion) were different. However, in both immature and ma-
ture DCs, plasma membrane arrival was began after a 15
min lag and was maximal by 60 min. Quantitation of these
data suggested that immature DCs actually transported a
slightly greater fraction (
 
 
 
30% more) of newly synthesized
Figure 1. MHC I surface expression is up-regu-
lated during DC maturation. (A) Immature
CD11c-positive DCs from day 4 C57BL/6J cul-
tures were purified using magnetic beads conju-
gated to anti-CD11c mAb. DCs were then replated
and activated by addition of LPS. At various times,
cells were harvested and the cell surface expression
of MHC I H-2Kb, MHC II I-Ab, and CD86 was
monitored by flow cytometry. Y-axis values repre-
sent the fold increase in surface expression of the
different markers. The values were obtained by di-
viding the median fluorescence index (MFI) at the
indicated time points by the MFI at time   0. For
the controls (nonstained cells and isotype control-
stained cells), the values were obtained by dividing
the MFI at the indicated time points by the MFI
measured with the specific Ab at time   0. In par-
allel, part of the cell samples were used for moni-
toring the expression of total MHC I HC by West-
ern blot. One representative experiment out of four
is shown. (B) Immature and mature (activated for
24 h by addition of LPS and cluster disruption)
DCs were fixed, permeabilized, and stained using
P8 (anti-HC- 2M complex), TIB 120 (anti-MHC
II) and either anti-KDEL (ER-resident KDEL pro-
teins) or anti-GM130 (Golgi marker), and analyzed
by confocal microscopy. (C) Immature and mature
(activated for 20 h by addition of LPS and cluster
disruption) CD11c-positive DCs were purified,
radiolabeled with 35S-methionine/cysteine, and
chased in unlabeled medium. At the indicated
times, cells were subject to surface biotinylation at
0 C. The resulting lysates were split into three un-
equal aliquots, two of which were used for immu-
noprecipitation of total HC and the assembled HC-
 2M complex. Cell surface MHC I was determined
by NeutrAvidin pull-down of immunoprecipitated
HC- 2M complexes. Autoradiograms of one ex-
periment (of two) are shown. Data from this ex-
periment were quantified by digital scanning and
plotted graphically as arbitrary units.T
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MHC I to the surface. MHC I was somewhat less stable at
the cell surface of immature DCs, presumably reflecting the
immature DC’s greater capacity for endocytosis, as found
for MHC II (14, 25).
Taken together, these data indicate that the enhanced
surface expression of MHC I in maturing DCs reflected
new protein synthesis rather than assembly and recruitment
of previously synthesized molecules.
 
Cross Presentation of Soluble OVA Follows the Classical
MHC I Pathway.
 
Although mature DCs are known to
stimulate CD8
 
 
 
 T cells better than immature DCs (16, 18,
19, 26), it is unknown if the formation of peptide–MHC I
complexes from exogenous antigen is subject to regulation.
To address this question, immature DCs were pulsed with
soluble OVA for 2 h, washed, and stimulated by adding LPS.
After dispersal of cell clusters by pipetting, the DCs were
chased for up to 24 h. The DCs were then fixed and cul-
tured with OT.1 CD8
 
 
 
 T cells specific for the H-2K
 
b
 
/OVA
complex. After being pulsed with 
 
 
 
0.5/ml of OVA, DCs
efficiently activated OT.1 T cells, with an optimal response
at 7 h after inducing DC maturation (Fig. 2 A), as previously
observed in D1 cells (6). Presentation was also 
 
 
 
95% inhib-
ited by the proteasome inhibitors lactacystin and epoxomi-
cin, and in DCs isolated from TAP1
 
 
 
/
 
 
 
 mice (unpublished
data). Thus, presentation of exogenous soluble OVA by
MHC I follows the classical MHC I pathway (5, 27, 28).
We also confirmed that exogenous OVA was trans-
ported to the cytosol, consistent with its reliance on the
classical pathway for MHC I presentation (5, 6). DC cul-
tures were pulsed with FITC-OVA for 30 min, washed,
transferred to coverslips, and incubated for 30 min at 37
 
 
 
C
to allow attachment. While OVA was always found in
MHC II-positive lysosomes (Fig. 2, B and C), many MHC
II-positive cells (
 
 
 
75%) also exhibited a diffuse cytosolic-
like staining (Fig. 2 C). Appearance of OVA in the cystosol
occurred rapidly, within 30 min after internalization and
receipt of the maturation stimulus, but long before the cells
achieved a mature phenotype.
OVA transport to the cytosol was also demonstrated by
subcellular fractionation. DC cultures were pulsed with
OVA as above and chased for 30 min after stimulation by
LPS and cluster disaggregation. After CD11c-positive DC
homogenization, cytosol was separated from membranes
and vesicles, and OVA detected by Western blot (Fig. 2
D). In total cell homogenates, four major bands were de-
tected (51 kD, 
 
 
 
45 kD, 
 
 
 
39 kD, and 
 
 
 
33 kD), with the
51 kD species corresponding to undigested OVA (right
lane). The 51 and 33 kD bands were predominant in the
membrane/vesicle fraction, presumably reflecting OVA
and OVA fragments in endosomes and lysosomes. In the
cytosol fraction, a clear 51 kD OVA was also detected,
along with a small amount of the 45 and 39 kD band. To
determine if the cytosolic OVA reflected the rupture of
OVA-containing lysosomes during homogenization, the
fractions were also probed for Cat L, a soluble content pro-
tein of lysosomes. Little if any Cat L was detected in the
cytosol fraction indicating that there was little lysosomal
rupture (Fig. 2 D).
 
CD11c-negative Cells Internalize and Transport Soluble
OVA Into the Cytosol but Do Not Exhibit Cross Presenta-
tion.
 
FITC-OVA was also internalized by 
 
 
 
60% of the
CD11c-negative, MHC II-negative cells (e.g., progenitors
or macrophages) that contaminate all DC cultures (Fig. 3
A). Surprisingly, in up to 75% of these cells, OVA was de-
tected in the cytosol (Fig. 3, B and C), although the pattern
of OVA fragments detected differed from those seen in
DCs (Fig. 2 D). Thus, egress of OVA or OVA fragments to
the cytosol did not appear to be a unique property of
CD11c-positive DCs.
We next asked if the CD11c-negative cells were capable
of cross presentation. The cultures were pulsed with OVA
for 2 h, washed, stimulated by LPS and cluster disruption,
and chased for 7 h. After fixation, CD11c-positive and
CD11c-negative populations were isolated. Only the
CD11c-positive fractions activated OT.1 T cells when ex-
posed to OVA (Fig. 3 D). In marked contrast, no activation
was seen with the CD11c-negative fraction, either in the
presence or absence of anti-CD28. CD11c-negative cells
were capable of presenting OVA peptide to OT.1 T cells
particularly in the presence of anti-CD28. Thus, despite
Figure 1 (continued)T
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being able to internalize OVA and transport OVA (or
OVA fragments) to the cytosol, the CD11c-negative popu-
lation was unable to mediate cross presentation.
 
CD11c-negative Cells and Immature CD11c-positive DCs
Can Form OVA Peptide–MHC I Complexes from Endogenously
Expressed OVA.
 
These results suggested that there are
additional steps downstream of antigen egress that were im-
portant elements of the cross presentation pathway; such
elements might be missing in CD11c-negative cells. It was
thus of interest to determine if the CD11c-negative cells
could form MHC I-peptide complexes from endogenously
expressed OVA. Using a recombinant retrovirus encoding
a cytoplasmic OVA construct, day 2 cultures were infected
to insert the construct into proliferating precursor cell pop-
ulations (12). CD11c-positive and –negative cells were as-
sayed by FACS
 
®
 
 using the 25D1.1.16 mAb specific for
OVA peptide/H2-Kb complex (29). As shown in Fig. 3 E,
significant reactivity was found on both populations, indi-
cating that both cell populations were capable of generating
the peptide–MHC I complex from endogenous OVA.
Thus, despite their inability to cross present internalized
OVA that had reached the cytosol, the CD11c-negative
cells could process and present endogenous antigen on
MHC I. Importantly, the CD11c-positive DCs used for
these experiments were of the immature (CD86-low) phe-
notype, as the cultures were not treated with LPS before
isolation. Thus, the OVA peptide–MHC I complex was
generated even in immature DCs, indicating that the en-
dogenous pathway was not dependent on DC maturation.
Cross Presentation of Exogenous OVA Is Differentially Regu-
lated by DC Maturation. Because peptide–MHC I com-
plexes could form from endogenous OVA in immature
DCs, we next asked if cross presentation by DCs is similarly
independent of DC maturation. Cultures were pulsed with
OVA for 2 h and washed carefully to avoid disruption of
cell clusters, itself a potential maturation stimulus (14). Af-
Figure 2. Cross presentation of soluble OVA
follows the classical MHC I pathway (A) Left panel:
immature B6D2F1 DCs were pulsed with indicated
concentrations of OVA (or BSA as a control) for
2 h, washed, activated by LPS addition and cluster
disruption. After a 7 h chase, the cells were fixed
and cultured with OT.1 CD8  T cells. Right
panel: after a 2 h pulse with OVA 1 mg/ml (or
BSA as a control), immature DCs were washed,
stimulated by LPS addition and cluster disruption,
chased for the indicated times, then fixed and added
to OT.1 T cells. T cell responses were monitored
by measuring IL-2 secretion. (B and C) Immature
DCs were pulsed with FITC-OVA (5 mg/ml) for
30 min, washed, transferred to coverslips after dis-
rupting DC clusters and incubated at 37 C for 30
min to allow cell attachment. DCs were then fixed,
permeabilized, and stained using a rabbit anti-OVA
Ab, and TIB 120 (anti-MHC II), and analyzed by
confocal microscopy. (D) DCs were pulsed with
OVA (5mg/ml) for 30 min, washed, and chased for
30 min after stimulation by LPS addition and clus-
ter disruption. CD11c-positive DCs were purified
using magnetic beads conjugated to anti-CD11c
mAb. After homogenization, cytosolic and mem-
brane/vesicle fractions were separated by ultracen-
trifugation, and probed for OVA and Cat L by
Western blot. One representative experiment out
of three is shown.T
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ter a 7 h chase, the cells were then fixed to prevent matura-
tion and cultured with OT.1 CD8  T cells. As shown in
Fig. 4 A (left panel), the unstimulated DCs were unable to
cross present OVA, suggesting that DC maturation was in
fact required to activate cross presentation. This was in
marked contrast to DCs subjected to dispersal of the cell
clusters by repeated pipetting and addition of LPS before
the 7 h culture period. These “LPS-treated and cluster dis-
rupted” DCs were efficient at cross presentation despite ex-
pressing no more MHC I than unstimulated cells (Fig. 4
B); presentation of preprocessed OVA peptide was similar
in all cases (Fig. 4 A, right panel). In fact, cluster disruption
alone was found to be a potent stimulus of cross presenta-
tion while LPS alone (in the absence of cluster disruption)
was almost totally ineffective (Fig. 4 A, left panel).
The inability of clustered DCs to mediate cross presenta-
tion did not appear to reflect an inability to transfer inter-
nalized OVA from endocytic compartments to the cytosol.
As found for cells treated by cluster disruption and LPS
(Fig. 2), intact OVA and OVA fragments were found in
the cytosolic fraction of the unstimulated DCs remaining in
clusters after exposure to antigen (Fig. 4 C). Appearance
in the cytosol fraction was temperature-dependent, how-
ever, as incubation of DC clusters with OVA at 0 C before
cell fractionation did not result in soluble or cytosolic OVA
(unpublished data).
Figure 3. CD11c-negative cells internalize and
transport soluble OVA into the cytosol but do not
exhibit cross presentation. (A) Immature B6D2F1
DC cultures were pulsed with FITC-OVA (5 mg/
ml) for 30 min, then washed. FITC-OVA uptake
and cell surface expression of CD11c were moni-
tored by flow cytometry. (B) DC cultures were
pulsed with OVA (5 mg/ml) for 30 min, washed,
and chased for 30 min. CD11c-negative cells were
separated from DCs using magnetic beads conju-
gated to anti-CD11c mAb. After homogenization
of CD11c-negative cells, cytosolic and membrane/
vesicle fractions were separated by ultracentrifuga-
tion, and probed for OVA and Cat L by Western
blot. (C) DC cultures were pulsed with FITC-
OVA (5 mg/ml) for 30 min, then washed. Cells
were transferred on coverslips and incubated at
37 C for 30 min to allow their attachment. Cells
were then fixed, permeabilized, and stained using a
rabbit anti-OVA Ab, and TIB 120 (anti-MHC II),
and analyzed by confocal microscopy. (D) DC cul-
tures were pulsed with 1 mg/ml of OVA for 2 h,
washed, activated with LPS and cluster disruption,
and chased for 7 h. After fixation, CD11c-positive
DCs were separated from CD11c-negative cells as
in B. Mixed cultures before separation of OVA-
pulsed cells (or BSA-pulsed cells as a control),
CD11c-positive and CD11c-negative fractions
( 95%) were then cultured with OT.1 T cells in
the presence or absence of anti-CD28 mAb. T cell
activation was monitored at 24 h by measuring IL-2
production. ND indicates “not done.” (E) Day 2
DC cultures were infected using a recombinant ret-
rovirus encoding a cytoplasmic OVA construct.
Cell surface expression of OVA/H2-Kb complexes
(x-axis) and CD86 (y-axis) was monitored by flow
cytometry on CD11c-negative and CD11c-posi-
tive cells at day 4. As a control noninfected cells
were used. One representative experiment out of
three is shown.T
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Similarly, “unstimulated,” 2 h OVA-pulsed DCs (i.e.,
cells not treated with added LPS and not subjected to clus-
ter disruption) also exhibited increased surface expression
of both CD86 and MHC II (Fig. 4 D). This effect was at-
tributable to OVA since “mock-treated” cells failed to in-
crease CD86 and MHC II levels unless LPS was added or
the clusters were dispersed before the 7 h culture (Fig. 4 E).
These results suggested that exposure to OVA alone trig-
gered at least some features of DC maturation. We assayed
various commercial sources of OVA for LPS and found
that all contained significant amounts of this contaminant.
Attempts to remove the contaminating LPS (e.g., by affin-
ity chromatography using Kuttsuclean [11]) were not suc-
cessful. While these results were initially bothersome, they
allowed an important conclusion, namely that not all matu-
ration stimuli were capable of activating cross presentation.
To examine this suggestion in greater detail, we tested
various stimuli known to induce DC maturation and
MHC II–restricted presentation for their capacity to pro-
mote cross presentation. OVA-pulsed DCs were cultured
for 7 h in the presence of each stimulus. Relative to “LPS
and cluster disruption” treatment, none of the stimuli
tested were able to promote cross presentation (Fig. 5 A).
This was despite the fact that all triggered phenotypic DC
maturation as indicated by increased expression of MHC
II and CD86 (Fig. 5 B) as well as MHC II presentation
(see below).
Since there was some variability in the extent to which
these agents stimulated phenotypic maturation, we asked if
the ability to induce cross presentation was time depen-
dent. OVA-pulsed DCs were therefore treated for 24 h
with each agent (unpublished data), at which time the
anti-CD40 Ab was also found to produce DCs capable of
stimulating OT.1 T cells. As shown in Fig. 5 C, DCs stim-
ulated by bacteria for up to 48 h were still unable to acti-
vate OT.1 T cells. In contrast, after 24 h of stimulation
with anti-CD40 Ab, DCs cross presented OVA and acti-
vated T cells, although to a somewhat lesser extent than
DCs matured by cluster disruption (Fig. 5 C, control).
Therefore, only “cluster disruption” and anti-CD40 Ab,
were capable of inducing cross presentation, albeit with
different efficiencies.
Cross Presentation of OVA Internalized Before DC Activa-
tion. Internalized antigens can be sequestered by imma-
ture DCs for extended periods (at least 60 h) before being
processed and loaded onto MHC II upon maturation (11).
We next determined if immature DCs could also sequester
antigens for cross presentation. OVA-pulsed DCs were
Figure 4. Cross presentation of soluble OVA is
differentially regulated by DC maturation. (A) Left
panel: immature B6D2F1 DCs were pulsed with
OVA or BSA (1 mg/ml) for 2h in 24 well-plates
where the cells were originally plated, washed care-
fully to avoid disruption of cell clusters (by adding
media slowly along the wall of each well and then
aspirating gently media at the same spot, repeat-
edly), and chased for 7 h with or without stimula-
tion before fixation and culture with OT.1 T cells.
Right panel: OVA-pulsed cells and T cells were
cultured in the presence of OVA peptide. T cell re-
sponses were monitored at 24 h by measuring IL-2
release. (B) After the pulse-chase, MHC I H-2Kb
surface expression was evaluated by flow cytometry
on the CD11c-positive population of “LPS-treated
and cluster disrupted” (solid black line) or unstimu-
lated OVA-pulsed cells (dashed black line). The
solid and dashed gray lines depict staining with an
isotype control on stimulated and unstimulated
cells, respectively. On the x-axis, the fluorescence
intensity is given, whereas the y-axis depicts the rel-
ative cell number. (C) DCs were pulsed with OVA
(5 mg/ml) for 30 min, washed, and chased for 30
min. CD11c-positive cells purified using magnetic
beads conjugated to anti-CD11c mAb. After ho-
mogenization, cytosolic and membrane/vesicle
fractions were separated, and probed for OVA and
Cat L by Western blot. (D) After 7 h in culture,
maturation state of “unstimulated” 2 h OVA-pulsed
DCs (i.e., not treated with added LPS and not sub-
jected to cluster disruption) and “mock-treated”
DCs was examined by measuring surface expression
of MHC II (x-axis) and CD86 (y-axis) by flow cy-
tometry on the CD11c-positive population. (E)
The capacity of the stimuli LPS and “cluster disrup-
tion” to trigger DC maturation was monitored on
the CD11c-positive population of unpulsed cultures
activated for 7 h as described above. One represen-
tative experiment out of three is shown.T
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chased for up to 48 h without further stimulation. At vari-
ous times of chase, the DCs were “cluster disrupted,” and
then incubated in presence of LPS for an additional 7 h be-
fore fixation and assay using OT.1 T cells. The DCs were
capable of cross presenting OVA that had been internalized
at least up to 48 h before receiving the activation stimulus
(Fig. 6 A). While the amount of cross presentation de-
creased with time, at 24 and 48 h, significant OT.1 T cell
responses were observed corresponding respectively to 45
and 25% of the amount of presentation exhibited by DCs
activated and assayed immediately after exposure to OVA.
These results suggested that an intracellular pool of
OVA is sequestered in endosomes or in the cytosol, or that
a pool of OVA peptide–MHC I complexes is retained in-
tracellularly (possibly in the ER), until the appropriate
stimulus is given to trigger cross presentation. To help dis-
tinguish between these possibilities, we examined the role
of the proteasome in presentation of previously internal-
ized OVA. After a 24 h chase and 30 min before DC stim-
ulation, epoxomicin was added. In the presence of the
drug, cross presentation was completely inhibited, al-
though there was no effect on the presentation of OVA
peptide (Fig. 6 B). This suggested that proteasome activity
was required to generate OVA peptides even 24 h after an-
tigen internalization. Thus, unstimulated DCs appear to
keep an intracellular pool of antigen sequestered, control-
ling cross presentation at least in part by controlling access
to the proteasome.
Presentation of OVA by MHC I and MHC II Is Differentially
Regulated. The results presented thus far have indicated
that various stimuli known to promote DC maturation
and enhance MHC II presentation were unable to activate
cross presentation. This suggests that although presentation
of exogenous antigens on both MHC I and MHC II are
Figure 5. Not all maturation stimuli induce cross
presentation. (A) Immature B6D2F1 DCs were
pulsed with OVA (1mg/ml) or BSA as a control for
2 h, washed, activated by addition of the indicated
stimuli, and chased for 7 h before fixation and cul-
ture with OT.1 T cells. T cell responses were
monitored at 24 h by measuring IL-2 release. (B)
Maturation was monitored at the level of cell sur-
face MHC II (x-axis) and CD86 (y-axis) by flow
cytometry on the CD11c-positive population of
unpulsed day 4 cultures activated with the indicated
stimuli for 7 h. (C) The procedure was the same as
described in panel A except that the DC cultures
were chased for the indicated periods after stimula-
tion with anti-CD40 Ab or bacteria. As a control,
OVA-pulsed DCs stimulated for 7 h by addition of
LPS and by cluster disruption were used. Results
are representative of three experiments. (*) indi-
cates below level of detection.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
120 Regulation of Cross Presentation during Dendritic Cell Maturation
subject to regulation, the two pathways are regulated dif-
ferentially. As procedures used to measure MHC II pre-
sentation by bone marrow–derived DCs typically (and
perhaps inadvertently) also involve a cluster disruption
step, it was critical to determine directly if cluster disrup-
tion might also be required for presentation on MHC II.
As OVA has both MHC I– and MHC II–restricted
epitopes, we were able to monitor its presentation on both
pathways in parallel.
OVA-pulsed DCs from B6D2F1 mice were cultured
with OT.1 CD8  T cells or the DO.11.10 CD4  T cell
hybridoma (specific for I-Ad /OVA complexes). As shown
in Fig. 7, DCs stimulated with LPS alone or LPS together
with cluster disruption exhibited comparable abilities to
activate DO.11.10 CD4  T cells. Thus, cluster disruption
was not required for MHC II presentation. As mentioned
earlier, our OVA contained detectable levels of endotox-
ins which induced DC maturation (unpublished data).
These results for MHC II presentation contrast dramati-
cally with those for MHC I cross presentation, as cross
presentation of the same antigen under the same condi-
tions was dependent on disrupting DC clusters before T
cell assay (Fig. 4 A).
Discussion
We have shown that presentation of exogenous antigens
by MHC I, like presentation by MHC II, is subject to de-
velopmental regulation in mouse bone marrow–derived
DCs. Although immature DCs are capable of accumulating
extracellular antigen intended for cross presentation, pre-
sentation will not occur until the cells are activated to ma-
ture. Rather unexpectedly, we also found that the signals
required for activating the MHC I and MHC II pathways
are at least in part distinct. An array of microbial products,
cytokines, and physical stimuli all activated the processing
and presentation of exogenous antigen on MHC II mole-
cules, but only a subset of these also facilitated MHC I cross
presentation of the same antigen. At a minimum, this find-
ing indicates that the exogenous MHC I and MHC II
pathways in bone marrow–derived DCs are differentially
regulated during DC maturation.
Several lines of evidence now indicate that DC matura-
tion itself is not a homogenous process leading to a single
species of mature, immunostimulatory cell. In the case of
MHC II responses, different stimuli produce mature DCs
that vary markedly in their cytokine release profiles and
thus in their functional properties. Maturation induced by
LPS or dsRNA produces DCs that secrete IL-12 and IFN- 
thus polarizing CD4  T cell responses to yield Th1 cells.
TNF -matured DCs, on the other hand, produce neither
IL-12 nor IFN- , and induce CD4  T cells to produce
both Th1 and Th2 cells (8, 16). Both types of DCs, how-
ever, are phenotypically mature and virtually indistinguish-
able on the basis of surface markers (e.g., high MHC II,
high costimulatory molecules). As yet unspecified signals
may produce “partially mature” DC populations found in
lymph nodes which process and present antigens on their
Figure 6. Cross presentation of OVA internalized prior DC activation.
(A) Immature B6D2F1 DC were pulsed with OVA or BSA as a control
(1 mg/ml) for 2 h, washed, and chased for 0 to 48 h before activation for
7 h with LPS and cluster disruption. Cells were then fixed and added to
OT.1 T cells. (B) After a 24 h chase and 30 min before activation, epoxo-
micin 1  M final was added to the cells and was also present during the
7 h stimulation period. As a control we used DMSO in which the drug was
stocked. Cells were then fixed and added to OT.1 T cells. Right panel:
OVA-pulsed cells and T cells were cultured in presence of OVA peptide.
At 24 h, as marker of T cell activation IL-2 secretion was measured. One
representative experiment out of three is shown, and the values represent
the mean of triplicate wells. (*) indicates below level of detection.
Figure 7. Presentation of OVA by MHC I and MHC II is differentially
regulated during DC maturation. Immature B6D2F1 DCs were pulsed
with OVA 1mg/ml (or BSA as a control) for 2 h, washed, activated or not
by addition of the indicated stimuli, and chased for 7 h before fixation and
culture with CD4  DO.11.10 T cells (specific for I-Ad/OVA). T cell re-
sponses were monitored at 24 h by measuring IL-2 release. One representa-
tive experiment out of  5 is shown.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
121 Delamarre et al.
MHC II but express low costimulatory molecules, a phe-
notype which may induce T cell tolerance rather than im-
munity (30, 31).
Out of the nine stimuli tested, all known to induce phe-
notypic DC maturation and to promote MHC II presenta-
tion, only two (cluster disruption and anti-CD40 Ab) also
activated MHC I cross presentation. That additional signals
might be needed to activate MHC I cross presentation by
DCs was first suggested by studies showing that the genera-
tion of CTL immunity is CD4  T helper dependent (32).
In vivo, anti-CD40 Ab can replace CD4  T cells suggest-
ing that CD40–CD40L interaction programs APCs to acti-
vate naive CD8  T cells (20–22). However, the nature of
this phenomenon at the cellular level, or the identity of the
APCs involved, has remained unknown. Our in vitro ex-
periments showed that anti-CD40 Ab induced phenotypic
DC maturation but also activated those aspects of the mat-
uration pathway that enabled cross presentation. Conceiv-
ably, anti-CD40 Ab acts similarly in vivo. The requirement
for CD4  T cells in triggering CTL responses in vivo may
also reflect the ligation of CD40 on DCs by CD40L on the
T cells. In vitro, the CD40L-negative CD4  T cell hy-
bridoma DO.11.10 was unable to activate cross presenta-
tion. The hybridoma did, however, trigger phenotypic DC
maturation indicating that T cells also have CD40L-inde-
pendent effects on immature DCs.
More effective at inducing cross presentation was the
“disruption” of the DC clusters by gentle pipetting. Al-
though this stimulus is well known to induce DC matura-
tion and MHC II presentation in vitro (14, 33), we do not
understand its mechanism. Cluster disruption may act by
briefly damaging the DC plasma membrane, inducing a
stress response (34). More likely, however, is a signal gen-
erated by disrupting cell–cell adhesion. Indeed, DC clusters
are stabilized by E-cadherin–mediated interactions with the
addition of anti-E-cadherin Ab actually opposing the in-
duction of maturation (35). While it is unlikely that disrup-
tion of homotypic interactions between immature DCs is
relevant in peripheral tissues, but E-cadherin–mediated ad-
hesion events seem likely to play an important role in
maintaining DC residence in epithelia (36). Conceivably,
“cluster disruption” in vitro mimics DC migration from
the epidermis in vivo.
Cross presentation is far more efficient in DCs than in
other cell types. Thus, it is likely that one or more of these
steps is specific to or amplified in DCs. These might also be
the steps subject to regulation. The initial release of inter-
nalized antigen from endosomes to the cytosol although is a
candidate, does not appear to be sufficient to allow cross
presentation as OVA was detected in the cytosol of unstim-
ulated DCs unable to cross present. Moreover, we found
that many CD11c-negative cells in our cultures also
seemed to have OVA in the cytosol yet were unable to
mediate cross presentation. This result suggests that there
are additional steps downstream of antigen egress that are
important elements of the cross presentation pathway in
DCs and that may be regulated during maturation.
DCs and CD11c-negative cells expressing OVA can
both process and present peptides derived from endoge-
nous OVA on MHC I, although they are unable to cross
present peptides derived from exogenous OVA. Thus,
these cells must possess the machinery for peptide process-
ing and loading onto MHC I, e.g., functional proteasomes,
transporter associated with antigen processing (TAP1/2),
and ER chaperone proteins assisting MHC I assembly and
peptide loading (1). This result suggests that the inability of
the cells to cross present lies between the antigen egress and
proteasome steps.
As virtually all nucleated cells present peptides derived
from endogenous proteins on MHC I to avoid killing by
NK cells, we suspect that the endogenous pathway is not
subject to the type of maturation-dependent regulation
seen for cross presentation. If so, then it must be that DCs
regulate only those components of the cross presentation
pathway that are not common to the endogenous pathway.
Alternatively, DCs possess mechanisms to selectively favor
one pathway over the other, perhaps (as suggested above)
by down-regulating the production of endogenous MHC I
ligands that may compete with trace amounts of exogenous
ligands internalized by endocytosis (24).
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